reviews on weight watchers semaglutide WeightWatchers Review: How this GLP-1 Program Works (2026) WeightWatchers to offer compounded version

The absence of strong clinical evidence validating the safety of microdosing underscores the importance of cautious, evidence-based approaches to medication management

Patients with obesity are more likely to discontinue GLP-1 therapy than those with diabetes, citing lower perceived necessity, stigma, and limited coverage as key drivers 7

Prospects for the next generation of obesity treatments focus on Fibroblast growth factor 21 (FGF21), ghrelin antagonism, GLP-1/glucagon coagonists, GLP-1/GIP/glucagon triple agonists, growth differentiation factor 15(GDF15), melaninconcentrating antagonists, and amylin-based therapies including pramlintide, cagrilintide, cagrilintid plus semaglutide [78]

However, these methods may carry additional risks and require careful consideration of injection technique, sterility, and absorption kinetics

In the second part of the session, Berenbaum explained the pleiotropic effects of GLP-1 and its receptors on metabolic, inflammatory, and tissue-protective pathways relevant to OA